Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
206. |
ECCT/17/03/05 | HOPE Sickle Cell Disease Clinical Study A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease |
Principal Investigator(s) 1. Videlis Nduba 2. Jessie Nyokabi Githanga Site(s) in Kenya 1. Gertrude\'s Children\'s Hospital (Nairobi City county) 2. Strathmore University Medical Center (Nairobi City county) 3. KEMRI CRDR Clinical Research clinic at Chandaria Health Center (Nairobi City county) 4. KEMRI Kondele Childrens Hospital Center for Clinical Research (Kisumu county) 5. KEMRI Clinical Research Center at Siaya County Referral Hospital (Siaya county) |
View |
207. |
ECCT/23/03/02 | Sunrise-3 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 |
Principal Investigator(s) 1. Dr. Paul Yonga 2. Dr John Kinuthia 3. DR LUCAS OTIENO TINA Site(s) in Kenya 1. Fountain Projects and Research Office, Clinical Research Centre (FOPRO-CRC) (Kisumu county) 2. KENYATTA NATIONAL HOSPITAL (Nairobi City county) 3. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
208. |
ECCT/20/06/03 | CVIA078 A Phase 2b randomized, open-label, controlled, single center study in Plasmodium falciparum-infected and uninfected adults age 18-55 years old in Kenya to evaluate the efficacy of the delayed, fractional dose RTS,S/AS01E malaria vaccine in subjects treated with artemisinin combination therapy plus primaquine |
Principal Investigator(s) 1. Nathanial Kelsey Copeland Site(s) in Kenya Kombewa Clinical Research Centre |
View |
209. |
ECCT/16/02/06 | A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults. A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP] |
Principal Investigator(s) 1. Christina Wesonga Obiero Site(s) in Kenya Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme |
View |
210. |
ECCT/23/11/01 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. AHERO CLINICAL TRIALS UNIT (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
View |